Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model

Table 6

Aortic dilation and wall thickness by optical coherence tomography analyses in WT and MFS mice with 6 months of age after losartan or lipoic acid treatments.

	Untreated		Losartan treatment		Lipoic acid treatment
	WT6	MFS6	WT6	MFS6	WT6	MFS6
	()	()	()	()	()	()
Aortic arch
Lumen (mm^2)	7.7 ± 0.2	12.2 ± 1.5	8.2 ± 0.9	6.3 ± 0.4	9.3 ± 0.6	16.0 ± 1.3^a–d
Thickness (mm)	5.2 ± 0.2	7.4 ± 0.1	5.1 ± 0.4	4.6 ± 0.4	5.7 ± 1.2	10.4 ± 1.2^e–g
Thoracic aorta
Lumen (mm^2)	7.1 ± 0.2	10.2 ± 0.3	7.5 ± 0.9	5.6 ± 0.5	8.1 ± 1.3	12.8 ± 1.2^e,g
Thickness (mm)	4.0 ± 0.1	6.2 ± 0.6^e	3.8 ± 0.2^h	4.0 ± 0.2^h	5.4 ± 0.4	8.4 ± 0.3^h–l
Abdominal aorta
Lumen (mm^2)	6.5 ± 0.2	10.9 ± 0.8^a	6.5 ± 0.9^m	4.3 ± 0.1^n	7.3 ± 0.3^g,h	10.6 ± 0.1^b,i,k,l
Thickness (mm)	6.1 ± 0.4	8.3 ± 0.1^a	6.5 ± 0.1^h	6.3 ± 0.1^m	6.6 ± 0.4^m	9.8 ± 0.1^i–k,o

WT: wild type; MFS: Marfan syndrome; 6: 6 months of age; ^a versus untreated WT6; ^b versus losartan treatment WT6; ^c versus losartan treatment MFS6; ^d versus lipoic acid treatment WT6; ^e versus untreated WT6; ^f versus losartan treatment WT6; ^g versus losartan treatment MFS6; ^h versus untreated MFS6; ⁱ versus untreated WT6; ^j versus losartan treatment WT6; ^k versus losartan treatment MFS6; ^l versus lipoic acid treatment WT6; ^m versus untreated MFS6; ⁿ versus untreated MFS6; ^o versus lipoic acid treatment WT6.